AstraZeneca will localize 10 drugs under SPIC arrangements

| By | AstraZeneca, Drug Manufacturing, Localization, SPIC
0
1052

In the next three years (by 2020), AstraZeneca intends to use the Special Investment Contract (SPIC) arrangements for localizing the manufacturing of 10 medicinal products, including 6 that have no analogs in Russia. In accordance with the current schedule of localization, these drugs will begin to arrive to commercial market at the end of 2019, said Irina Panarina, the General Director of AstraZeneca Russia & Eurasia.

One of the localized products will be osimertinib, an EGFR tyrosine kinase inhibitor for the treatment of T790M mutation-positive non-small cell lung cancer (NSCLC). The drug will be produced at the company’s plant in Vorsino Industrial Park (Kaluga region), and its production line has already been tested and is ready for the launch.

“In the world, there are only two other sites capable of manufacturing this targeted drug. They are in Sweden and China, and now we also have a site in Russia. We are the third country in the world that will manufacture osimertinib,” said Irina Panarina. She added that this demonstrated the high importance of the Russian market for the pharmaceutical company.

In October 2017, AstraZeneca became the first pharmaceutical company to sign a SPIC. Under the special investment contract, the pharmaceutical manufacturer plans to make additional investments of more than 1 billion rubles in upgrading and organizing the Russian production facilities to manufacture the drugs for the treatment of socially important diseases.